IRD Latest Press Releases

-- October 29, 2026 --

Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations Globe Newswire 7:00 AM

-- October 21, 2026 --

Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness Globe Newswire 7:00 AM

-- October 16, 2026 --

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia Globe Newswire 12:00 PM

-- October 15, 2026 --

Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 Globe Newswire 4:00 PM

-- October 13, 2026 --

Opus Genetics to Present at the Chardan Annual Healthcare Conference Globe Newswire 7:00 AM

-- September 10, 2026 --

Big Pharma Setbacks Create a New Wave of Rebound Plays Globe Newswire 2:12 PM

-- September 9, 2026 --

Four Biotech Stories Heating Up Right Now Globe Newswire 11:55 AM

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 Globe Newswire 7:00 AM

-- September 2, 2026 --

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences Globe Newswire 7:00 AM

-- August 19, 2026 --

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer Globe Newswire 4:05 PM

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 6, 2026 --

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update Globe Newswire 7:00 AM

-- August 3, 2026 --

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease Globe Newswire 7:00 AM

-- July 9, 2026 --

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results Globe Newswire 7:00 AM

-- July 6, 2026 --

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease Globe Newswire 7:00 AM

-- June 26, 2026 --

Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes Globe Newswire 9:15 AM

-- June 16, 2026 --

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases Globe Newswire 4:05 PM

-- June 2, 2026 --

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes